China dismisses researchers after fatal gene-editing trial of child

Chinese authorities have dismissed two researchers and disciplined five others following an investigation into an experimental gene-editing trial that resulted in the death of a six-year-old girl. The Shanghai municipal government found that the team failed to report preclinical safety signals, omitted death risks from informed consent forms, and concealed the child's death in published papers. The case highlights systemic oversight gaps in China's investigator-initiated trial framework, prompting stricter regulations and institutional self-examinations.
Key points
- Shanghai authorities dismissed Zilong Qiu, a neuroscientist at Shanghai Jiao Tong University, and a deputy researcher at Xinhua Hospital, barring both from government science projects for five years.
- The investigation found the team ignored preclinical toxicology data showing liver damage in monkeys and failed to disclose the child's death in a journal paper.
- The girl, who had Snijders Blok-Campeau syndrome, died of medical complications after receiving a viral vector therapy at Xinhua Hospital in March 2025.
- Families provided researchers with gifts and money totaling 1.1 million yuan, which were not disclosed in the research paper.
- China implemented new rules in May 2026 to tighten oversight of investigator-initiated trials, limiting which sites can run such studies.
Background
This incident follows a broader scrutiny of China's biotechnology sector, where rapid clinical development has outpaced regulatory oversight. In August 2026, Stat reported the death of a boy in a separate CRISPR trial for Duchenne muscular dystrophy, drawing international attention to safety gaps. Our archive notes that China has been implementing new rules on investigator-initiated trials to address these concerns, while global biotech firms like Cellectis are pivoting strategies due to shifting commercial landscapes.
How outlets are covering it
CCTV and Bloomberg emphasize the disciplinary actions and regulatory reforms, highlighting the dismissal of key personnel and the five-year ban on government projects. Nature provides detailed context on the specific failures, including the ignored primate safety data and the ethics committee's approval of the trial without required safety materials. Retraction Watch, which first reported the case in July, frames the incident as a critical failure in transparency and oversight, noting the lack of public registration and independent safety monitoring. All sources agree that the case exposes systemic issues in China's fast-track trial pathway, though Nature and Retraction Watch focus more on the scientific and ethical breaches, while CCTV and Bloomberg highlight the administrative consequences and new regulatory measures.
Why it matters
The case underscores the risks of accelerated clinical trials without adequate safety oversight, particularly in high-growth biotech sectors. It may influence global standards for gene therapy trials and prompt stricter international scrutiny of China's biomedical research practices. The disciplinary actions and new regulations signal a shift toward greater transparency and accountability in clinical research, potentially affecting future trial approvals and public trust in gene editing therapies.
What to watch
Multiple organizations in China are required to submit written self-examinations and rectify identified failings. Authorities plan to strengthen oversight of clinical trials involving new biomedical technologies, including gene editing therapies. The new rules on investigator-initiated trials, implemented in May 2026, will limit which sites can run such studies and impose additional requirements, aiming to prevent similar incidents in the future.
- Chinese scientists fired after child dies in gene editing study: report Fierce Biotech
- Chinese scientist sacked after child died in gene-editing trial Nature
- Weekend reads: China fires researchers after death during trial; Critics question ‘baffling’ disease data; Retractions of old papers on the rise Retraction Watch
- China Fires Researchers After Child Dies in Gene-Editing Trial Bloomberg.com
- China tightens IIT oversight to safeguard CGT data integrity The Pharma Letter
Want the full story? Read the original reporting
Read on Fierce Biotech